

**TABLE 78: INCLUDED STUDY CHARACTERISTICS: TREATMENT-NAIVE (N = 21)**

AUTHOR, YEAR, STUDY NAME (IF AVAILABLE)	TOTAL N	POPULATION	TREATMENTS	COUNTRIES	PHASE	RANDOMIZED (Y/N)	GENOTYPE						
							1	2	3	4	5	6	
<b>Included in the NMA (SVR)</b>													
Afdhal et al., 2014 ION-1	870	≥ 18 years Genotype 1 ≤ 20% of patients with cirrhosis	SOF12 + LDV12 SOF24 + LDV24 SOF12 + LDV12 + RBV12 SOF24 + LDV24 + RBV24	USA, Europe	3	Yes	Y						
Feld et al., 2014 SAPPHIRE-I	636	18 to 70 years Genotype 1 No cirrhosis	PAR/RIT12 + OMB12 + DAS12 + RBV12	N. America, Europe, and Australia	3	Yes	Y						
Ferenci et al., 2014 PEARL-III	419	18 to 70 years Genotype 1b No evidence of cirrhosis	PAR/RIT12 + OMB12 + DAS12	USA, Asia, Europe	3	Yes	Y						
Ferenci et al., 2014 PEARL-IV	305	18 to 70 years Genotype 1b No evidence of cirrhosis	PAR/RIT12 + OMB12 + DAS12 + RBV12	Canada, USA, UK	3	Yes	Y						
Jacobson et al., 2014 QUEST-1	395	≥ 18 years Genotype 1 Patients with cirrhosis eligible	PR48 SIM12 + PR24-48 RGT	Canada, USA, Europe, and other countries	3	Yes	Y						

AUTHOR, YEAR, STUDY NAME (IF AVAILABLE)	TOTAL N	POPULATION	TREATMENTS	COUNTRIES	PHASE	RANDOMIZED (Y/N)	GENOTYPE							
							1	2	3	4	5	6		
Kohli et al., 2015	60	≥ 18 years Genotype 1 ≤ 20% of patients with compensated cirrhosis	SOF12 + LDV12	USA	2a	No	Y							
Kowdley et al., 2013 ATOMIC	332	> 18 years Genotype 1 No cirrhosis	SOF12 + PR12	USA, Puerto Rico	2	Yes	Y							
Kowdley et al., 2014 ION-3	647	≥ 18 years Genotype 1 No cirrhosis	SOF12 + LDV12 SOF8 + LDV8 SOF8 + LDV8 + RBV8	USA	3	Yes	Y							
Lawitz et al., 2013 FISSION	527	> 18 years Genotype 2 or 3 With or without cirrhosis	SOF12 + RBV12 PR24	Canada, USA, Asian, Europe	3	Yes		Y						
Lawitz et al., 2013 NEUTRINO	327	> 18 years Genotype 1, 4, 5, 6 With or without cirrhosis	SOF12 + PR12	USA	3	No	Y			Y	Y	Y		
Lawitz et al., 2013-1	122	18 to 70 years Genotype 1, 2 or 3 No cirrhosis	SOF12 PR24-48 RGT PR48	USA	2	Yes	Y							

AUTHOR, YEAR, STUDY NAME (IF AVAILABLE)	TOTAL N	POPULATION	TREATMENTS	COUNTRIES	PHASE	RANDOMIZED (Y/N)	GENOTYPE							
							1	2	3	4	5	6		
Manns et al., 2014 QUEST-2	393	≥ 18 years Genotype 1 Patients with cirrhosis eligible	PR48 SIM12 PR24-48 RGT	USA, Europe, S. America	3	Yes	Y							
Osinusi et al., 2013 SPARE-1	10	> 18 years Genotype 1 No cirrhosis	SOF24 + RBV24	USA	2a	No	Y							
Osinusi et al., 2013 SPARE-2	50	> 18 years Genotype 1 ≤ 20% of patients may have cirrhosis	SOF24 + RBV24 SOF24 + RBV (low dose) 24	USA	2a	Yes	Y							
Osinusi et al., 2015	50	≥ 18 years Genotype 1 No cirrhosis HIV coinfection	SOF12 + LDV12	USA	2b	No	Y							
Sulkowski et al., 2013 P05411	99	18 to 65 years Genotype 1 HIV coinfection	PR48 B44 PR48	Canada, USA, Argentina, Brazil, Europe	2	Yes	Y							
Sulkowski et al., 2013	60	18 to 65 years Genotype 1 HIV coinfection	PR48 T12 PR48 q8	USA, Europe	2a	Yes	Y							

AUTHOR, YEAR, STUDY NAME (IF AVAILABLE)	TOTAL N	POPULATION	TREATMENTS	COUNTRIES	PHASE	RANDOMIZED (Y/N)	GENOTYPE					
							1	2	3	4	5	6
<b>Not included in the NMA for All SVR</b>												
Hassanein et al., 2015	21	18 to 70 years Genotype 1 No evidence of cirrhosis	DCV12 + ASU12 + BEC12 (75 mg b.i.d.) DCV12 + ASU12 + BEC12 (150 mg b.i.d.)	USA	2a	Yes					N	
Lawitz et al., 2013-2	25	18 to 70 years Genotype 1, 2 or 3 No cirrhosis	SOF12 + PR12	USA	2	No	Y	Y				
Rodriguez-Torres et al., 2015	23	≥ 21 years Genotype 1 to 6 No evidence of cirrhosis HIV-1 coinfection	SOF12 + PR12	Puerto Rico	2	No	Y	Y	Y	Y	Y	Y
Zeuzem et al., 2015 C-EDGE	421	≥ 18 years Genotype 1, 4, or 6 (15% of patients having GT4 or GT6 infection) 20% of patients having cirrhosis	GRZ12 + ELB12	USA, Europe, Australia, Scandinavia, and Asia	3	Yes	Y			Y		Y

ASU = asunaprevir; BEC = beclabuvir; b.i.d. = twice daily; DAS = dasabuvir; DCV = daclatasvir; ELB = elbasvir; GRZ = grazoprevir; GT = genotype; LDV = ledipasvir; NMA = network meta-analysis; OMB = ombitasvir; PAR = paritaprevir; PR = pegylated interferon plus ribavirin; RBV = ribavirin; RGT = response-guided therapy; RIT = ritonavir; SIM = simeprevir; SOF = sofosbuvir; SVR = sustained virologic response; T = telaprevir.

Note: Please refer to Treatment Regimen Nomenclature table for description of dosages.